$10B M&A Deal Pays Off With GSK's First Lung Cancer Drug Approval

GSK's $10.6bn acquisition of Nuvalent has delivered its first FDA approval: Jideytro (zidesamtinib), a ROS1 inhibitor for advanced non-small cell lung cancer, approved ahead of schedule. The drug addresses an estimated 50,000 annual diagnoses of ROS1-positive NSCLC worldwide.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.